

BREAST CANCER

3698 samples - 13.51 % of the cohort (P: 1909 - 51.6 % | M: 1789 - 48.4 %)

2736 samples with TP53 hits - 73.99 % (P: 1335 - 48.8 % | M: 1401 - 51.2 %)



NON-SMALL CELL LUNG CANCER

3469 samples - 12.67 % of the cohort (P: 2109 - 60.8 % | M: 1360 - 39.2 %)

2654 samples with TP53 hits - 76.51 % (P: 1480 - 55.8 % | M: 1174 - 44.2 %)








2682 samples - 9.8 % of the cohort (P: 1830 - 68.2 % | M: 852 - 31.8 %)
2264 samples with TP53 hits - 84.41 % (P: 1495 - 66.0 % | M: 769 - 34.0 %)



GLIOMA

1408 samples - 5.14 % of the cohort (P: 1317 - 93.5 % | M: 91 - 6.5 %)


588 samples with TP53 hits - 41.76 % (P: 552 - 93.9 % | M: 36 - 6.1 %)



PROSTATE CANCER

1342 samples - 4.9 % of the cohort (P: 724 - 53.9 % | M: 618 - 46.1 %)

757 samples with TP53 hits - 56.41 % (P: 347 - 45.8 % | M: 410 - 54.2 %)



PANCREATIC CANCER
1257 samples - 4.59 % of the cohort (P: 656 - 52.2 % | M: 601 - 47.8 %)
1017 samples with TP53 hits - 80.91 % (P: 520 - 51.1 % | M: 497 - 48.9 %)



SKIN CANCER, NON-MELANOMA

216 samples - 0.79 % of the cohort (P: 109 - 50.5 % | M: 107 - 49.5 %)

138 samples with TP53 hits - 63.89 % (P: 66 - 47.8 % | M: 72 - 52.2 %)



ENDOMETRIAL CANCER

946 samples - 3.46 % of the cohort (P: 648 - 68.5 % | M: 297 - 31.4 %)

530 samples with TP53 hits - 56.03 % (P: 358 - 67.5 % | M: 172 - 32.5 %)





OVARIAN CANCER

859 samples - 3.14 % of the cohort (P: 366 - 42.6 % | M: 493 - 57.4 %)

740 samples with TP53 hits - 86.15 % (P: 298 - 40.3 % | M: 442 - 59.7 %)



827 samples - 3.02 % of the cohort (P: 498 - 60.2 % | M: 329 - 39.8 %)
463 samples with TP53 hits - 55.99 % (P: 281 - 60.7 % | M: 182 - 39.3 %)



CANCER OF UNKNOWN PRIMARY

771 samples - 2.82 % of the cohort (P: 84 - 10.9 % | M: 687 - 89.1 %)






557 samples with TP53 hits - 72.24 % (P: 58 - 10.4 % | M: 499 - 89.6 %)



HEPATOBIILIARY CANCER

688 samples - 2.51 % of the cohort (P: 490 - 71.2 % | M: 198 - 28.8 %)

415 samples with TP53 hits - 60.32 % (P: 282 - 68.0 % | M: 133 - 32.0 %)













ESOPHAGOGASTRIC CANCER
629 samples - 2.3 % of the cohort (P: 459 - 73.0 % | M: 170 - 27.0 %)
549 samples with TP53 hits - 87.28 % (P: 399 - 72.7 % | M: 150 - 27.3 %)



RENAL CELL CARCINOMA

613 samples - 2.24 % of the cohort (P: 403 - 65.7 % | M: 210 - 34.3 %)

273 samples with TP53 hits - 44.54 % (P: 165 - 60.4 % | M: 108 - 39.6 %)



GERM CELL TUMOR

378 samples - 1.38 % of the cohort (P: 232 - 61.4 % | M: 146 - 38.6 %)

320 samples with TP53 hits - 84.66 % (P: 189 - 59.1 % | M: 131 - 40.9 %)



GASTROINTESTINAL STROMAL TUMOR

399 samples - 1.46 % of the cohort (P: 242 - 60.7 % | M: 157 - 39.3 %)

118 samples with TP53 hits - 29.57 % (P: 56 - 47.5 % | M: 62 - 52.5 %)



THYROID CANCER
 391 samples - 1.43 % of the cohort (P: 165 - 42.2 % | M: 226 - 57.8 %)
 157 samples with TP53 hits - 40.15 % (P: 77 - 49.0 % | M: 80 - 51.0 %)



HEAD AND NECK CANCER

350 samples - 1.28 % of the cohort (P: 158 - 45.1 % | M: 192 - 54.9 %)

221 samples with TP53 hits - 63.14 % (P: 108 - 48.9 % | M: 113 - 51.1 %)



NON-SMALL CELL LUNG CANCER

3469 samples - 12.67 % of the cohort (P: 2109 - 60.8 % | M: 1360 - 39.2 %)

2654 samples with TP53 hits - 76.51 % (P: 1480 - 55.8 % | M: 1174 - 44.2 %)



BONE CANCER

218 samples - 0.8 % of the cohort (P: 119 - 54.6 % | M: 99 - 45.4 %)

135 samples with TP53 hits - 61.93 % (P: 74 - 54.8 % | M: 61 - 45.2 %)



SKIN CANCER, NON-MELANOMA

216 samples - 0.79 % of the cohort (P: 109 - 50.5 % | M: 107 - 49.5 %)

138 samples with TP53 hits - 63.89 % (P: 66 - 47.8 % | M: 72 - 52.2 %)




















MESOTHELIOMA

222 samples - 0.81 % of the cohort (P: 184 - 82.9 % | M: 38 - 17.1 %)

104 samples with TP53 hits - 46.85 % (P: 84 - 80.8 % | M: 20 - 19.2 %)



SALIVARY GLAND CANCER
207 samples - 0.76 % of the cohort (P: 65 - 31.4 % | M: 142 - 68.6 %)
97 samples with TP53 hits - 46.86 % (P: 31 - 32.0 % | M: 66 - 68.0 %)



UTERINE SARCOMA

179 samples - 0.65 % of the cohort (P: 83 - 46.4 % | M: 96 - 53.6 %)

112 samples with TP53 hits - 62.57 % (P: 57 - 50.9 % | M: 55 - 49.1 %)



PERIPHERAL NERVOUS SYSTEM
171 samples - 0.63 % of the cohort (P: 87 - 50.9 % | M: 84 - 49.1 %)
85 samples with TP53 hits (P: 44 - 51.8 % | M: 41 - 48.2 %)

